These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Modified oligopeptides designed to interact with the HIV-1 proteinase inhibit viral replication. Grinde B; Hungnes O; Tjøtta E Arch Virol; 1990; 114(3-4):167-73. PubMed ID: 2241573 [TBL] [Abstract][Full Text] [Related]
6. Determination of the relative binding free energies of peptide inhibitors to the HIV-1 protease. Ferguson DM; Radmer RJ; Kollman PA J Med Chem; 1991 Aug; 34(8):2654-9. PubMed ID: 1652028 [No Abstract] [Full Text] [Related]
7. Antiviral activity and cross-resistance profile of P-1946, a novel human immunodeficiency virus type 1 protease inhibitor. Sévigny G; Stranix B; Tian B; Dubois A; Sauvé G; Petropoulos C; Lie Y; Hellmann N; Conway B; Yelle J Antiviral Res; 2006 Jun; 70(2):17-20. PubMed ID: 16473417 [TBL] [Abstract][Full Text] [Related]
8. Bile pigments as HIV-1 protease inhibitors and their effects on HIV-1 viral maturation and infectivity in vitro. McPhee F; Caldera PS; Bemis GW; McDonagh AF; Kuntz ID; Craik CS Biochem J; 1996 Dec; 320 ( Pt 2)(Pt 2):681-6. PubMed ID: 8973584 [TBL] [Abstract][Full Text] [Related]
10. Haloperidol-based irreversible inhibitors of the HIV-1 and HIV-2 proteases. De Voss JJ; Sui Z; DeCamp DL; Salto R; Babé LM; Craik CS; Ortiz de Montellano PR J Med Chem; 1994 Mar; 37(5):665-73. PubMed ID: 8126707 [TBL] [Abstract][Full Text] [Related]
11. Inhibitory effect of carnosic acid on HIV-1 protease in cell-free assays [corrected]. Paris A; Strukelj B; Renko M; Turk V; Pukl M; Umek A; Korant BD J Nat Prod; 1993 Aug; 56(8):1426-30. PubMed ID: 8229021 [TBL] [Abstract][Full Text] [Related]
12. Synthesis of novel inhibitors of the HIV-1 protease: difunctional enols of simple N-protected amino acids. Vaillancourt M; Vanasse B; Le Berre N; Cohen E; Sauvé G Bioorg Med Chem; 1994 May; 2(5):343-55. PubMed ID: 7922146 [TBL] [Abstract][Full Text] [Related]
13. HIV-1 evolution under pressure of protease inhibitors: climbing the stairs of viral fitness. Berkhout B J Biomed Sci; 1999; 6(5):298-305. PubMed ID: 10494036 [TBL] [Abstract][Full Text] [Related]
14. A novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI), GRL-98065, is potent against multiple-PI-resistant human immunodeficiency virus in vitro. Amano M; Koh Y; Das D; Li J; Leschenko S; Wang YF; Boross PI; Weber IT; Ghosh AK; Mitsuya H Antimicrob Agents Chemother; 2007 Jun; 51(6):2143-55. PubMed ID: 17371811 [TBL] [Abstract][Full Text] [Related]
15. Statine based tripeptides as potent inhibitors of HIV-1 replication. Fehrentz JA; Chomier B; Bignon E; Venaud S; Chermann JC; Nisato D Biochem Biophys Res Commun; 1992 Oct; 188(2):873-8. PubMed ID: 1445328 [TBL] [Abstract][Full Text] [Related]
16. Inhibition of the human immunodeficiency virus-1 protease and human immunodeficiency virus-1 replication by bathocuproine disulfonic acid Cu1+. Davis DA; Branca AA; Pallenberg AJ; Marschner TM; Patt LM; Chatlynne LG; Humphrey RW; Yarchoan R; Levine RL Arch Biochem Biophys; 1995 Sep; 322(1):127-34. PubMed ID: 7574666 [TBL] [Abstract][Full Text] [Related]
17. Cross-resistance within the protease inhibitor class. Race E Antivir Ther; 2001; 6 Suppl 2():29-36. PubMed ID: 11678476 [No Abstract] [Full Text] [Related]
18. Enhanced replication of R5 HIV-1 isolates in vitro by a small-molecule reagent targeting HIV-1 protease. Wardle NJ; Hudson HR; Matthews RW; Nunn CM; Vella C; Bligh SW ChemMedChem; 2013 May; 8(5):719-21. PubMed ID: 23509042 [TBL] [Abstract][Full Text] [Related]